JACC:经皮除颤器植入的安全性和疗效性研究

2017-08-10 MedSci MedSci原创

经皮电复律除颤器的植入(S-ICD)是用来治疗室性心律失常的技术,S-ICD临床结果和成本效益因素评价(EFFORTLESS S-ICD)的数据库记录了985名患者5年的随访预后情况。近日,在国际心血管权威杂志JACC上发表了一篇旨在通过EFFORTLESS S-ICD数据库评估分析S-ICD的安全性和不良休克发生率的临床研究。本研究的主要终点事件是术后30天和360天的并发症,心房颤动或室上性心

经皮电复律除颤器的植入(S-ICD)是用来治疗室性心律失常的技术,S-ICD临床结果和成本效益因素评价(EFFORTLESS S-ICD)的数据库记录了985名患者5年的随访预后情况。近日,在国际心血管权威杂志JACC上发表了一篇旨在通过EFFORTLESS S-ICD数据库评估分析S-ICD的安全性和不良休克发生率的临床研究。本研究的主要终点事件是术后30天和360天的并发症,心房颤动或室上性心动过速所致的休克。队列的平均随访时间是3.1 ± 1.5年,有82名患者完成了完整的5年随访调查,患者的平均年龄是48岁,女性占28%,左室射血分数为43 ± 18%,65%的患者建议首次接受介入治疗。研究结果显示,S-ICD的手术并发症在30天和360天分别是4.1%和8.4%。少数患者由于心动过速(n=5)、双心室起搏(n=4)或心动过缓(n=1)而需要将植入设备取出。休克的发生率在1年和3.1年的分别是8.1%和11.7%。在植入的患者中,99.5%取得了理想的疗效。研究结果表明,经皮电复律除颤器的植入的安全性和有效性是值得肯定的。原始出处:Lucas B et al.Implant a

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853721, encodeId=f3991853e211f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 14 01:13:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325469, encodeId=a47b13254692e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439139, encodeId=2c16143913981, content=<a href='/topic/show?id=8e3a98396f2' target=_blank style='color:#2F92EE;'>#除颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98396, encryptionId=8e3a98396f2, topicName=除颤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520392, encodeId=6a2c152039255, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232231, encodeId=bd0f2322314d, content=研究设计有创新性, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfGccQGCB4aeJK5D3ibPlZfB4mO50cwGAa6xz9uorDUr0FT59IwUMUYkiaFauF3AlibI8nVj81lYz9dfMEAp6IOrHX/0, createdBy=74421964351, createdName=ishtar, createdTime=Thu Aug 10 21:17:04 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232189, encodeId=d67123218915, content=方便快捷恢复快, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Thu Aug 10 15:40:53 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2017-12-14 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853721, encodeId=f3991853e211f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 14 01:13:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325469, encodeId=a47b13254692e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439139, encodeId=2c16143913981, content=<a href='/topic/show?id=8e3a98396f2' target=_blank style='color:#2F92EE;'>#除颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98396, encryptionId=8e3a98396f2, topicName=除颤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520392, encodeId=6a2c152039255, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232231, encodeId=bd0f2322314d, content=研究设计有创新性, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfGccQGCB4aeJK5D3ibPlZfB4mO50cwGAa6xz9uorDUr0FT59IwUMUYkiaFauF3AlibI8nVj81lYz9dfMEAp6IOrHX/0, createdBy=74421964351, createdName=ishtar, createdTime=Thu Aug 10 21:17:04 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232189, encodeId=d67123218915, content=方便快捷恢复快, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Thu Aug 10 15:40:53 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853721, encodeId=f3991853e211f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 14 01:13:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325469, encodeId=a47b13254692e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439139, encodeId=2c16143913981, content=<a href='/topic/show?id=8e3a98396f2' target=_blank style='color:#2F92EE;'>#除颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98396, encryptionId=8e3a98396f2, topicName=除颤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520392, encodeId=6a2c152039255, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232231, encodeId=bd0f2322314d, content=研究设计有创新性, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfGccQGCB4aeJK5D3ibPlZfB4mO50cwGAa6xz9uorDUr0FT59IwUMUYkiaFauF3AlibI8nVj81lYz9dfMEAp6IOrHX/0, createdBy=74421964351, createdName=ishtar, createdTime=Thu Aug 10 21:17:04 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232189, encodeId=d67123218915, content=方便快捷恢复快, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Thu Aug 10 15:40:53 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2017-08-12 zhouqu_8
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853721, encodeId=f3991853e211f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 14 01:13:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325469, encodeId=a47b13254692e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439139, encodeId=2c16143913981, content=<a href='/topic/show?id=8e3a98396f2' target=_blank style='color:#2F92EE;'>#除颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98396, encryptionId=8e3a98396f2, topicName=除颤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520392, encodeId=6a2c152039255, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232231, encodeId=bd0f2322314d, content=研究设计有创新性, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfGccQGCB4aeJK5D3ibPlZfB4mO50cwGAa6xz9uorDUr0FT59IwUMUYkiaFauF3AlibI8nVj81lYz9dfMEAp6IOrHX/0, createdBy=74421964351, createdName=ishtar, createdTime=Thu Aug 10 21:17:04 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232189, encodeId=d67123218915, content=方便快捷恢复快, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Thu Aug 10 15:40:53 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2017-08-12 jiyangfei
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853721, encodeId=f3991853e211f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 14 01:13:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325469, encodeId=a47b13254692e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439139, encodeId=2c16143913981, content=<a href='/topic/show?id=8e3a98396f2' target=_blank style='color:#2F92EE;'>#除颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98396, encryptionId=8e3a98396f2, topicName=除颤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520392, encodeId=6a2c152039255, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232231, encodeId=bd0f2322314d, content=研究设计有创新性, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfGccQGCB4aeJK5D3ibPlZfB4mO50cwGAa6xz9uorDUr0FT59IwUMUYkiaFauF3AlibI8nVj81lYz9dfMEAp6IOrHX/0, createdBy=74421964351, createdName=ishtar, createdTime=Thu Aug 10 21:17:04 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232189, encodeId=d67123218915, content=方便快捷恢复快, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Thu Aug 10 15:40:53 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2017-08-10 ishtar

    研究设计有创新性

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1853721, encodeId=f3991853e211f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Dec 14 01:13:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325469, encodeId=a47b13254692e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439139, encodeId=2c16143913981, content=<a href='/topic/show?id=8e3a98396f2' target=_blank style='color:#2F92EE;'>#除颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98396, encryptionId=8e3a98396f2, topicName=除颤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520392, encodeId=6a2c152039255, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Sat Aug 12 06:13:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232231, encodeId=bd0f2322314d, content=研究设计有创新性, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfGccQGCB4aeJK5D3ibPlZfB4mO50cwGAa6xz9uorDUr0FT59IwUMUYkiaFauF3AlibI8nVj81lYz9dfMEAp6IOrHX/0, createdBy=74421964351, createdName=ishtar, createdTime=Thu Aug 10 21:17:04 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232189, encodeId=d67123218915, content=方便快捷恢复快, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Thu Aug 10 15:40:53 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2017-08-10 楠博One

    方便快捷恢复快

    0

相关资讯

JACC:卡格列净能降低2型糖尿病患者的心血管标志物

研究显示钠-葡萄糖转运蛋白2抑制剂(SGLT-2i)可能降低2型糖尿病患者心血管和心衰的发病风险。近日,在国际心血管权威杂志JACC上发表了一篇旨在评估卡格列净(canagliflozin)对老年2型糖尿病患者心血管标志物影响的临床研究。本研究将666名T2DM患者随机分成卡格列净100或300mg治疗组和安慰剂组。评估了从基线到26、52周和104周患者血清N末端B型钠尿肽(NT-proBNP)

JAHA:血小板凝聚状态能预测冠心病患者的临床风险?

既往研究表明,在冠心病患者中,在接受抗血小板治疗期间出现不断升高的血小板聚集可能会增加心血管不良事件的发生风险,而大多数冠心病患者接受的是单一的阿司匹林治疗。近日,在国际心血管权威杂志JAHA上发表了一篇旨在评估接受阿司匹林治疗的稳定冠心病患者的高血小板凝聚水平是否会增加心血管不良事件的发生风险的临床研究。本研究纳入了900例有心梗病史或2型糖尿病病史的稳定冠心病患者,所有患者均接受单一的每天75

JACC:基于生物标志物的冠心病预后预测模型

目前,尚无公认的预测稳定型冠心病预后的模型。近日,在国际心血管权威杂志JACC上发表了一篇旨在比较评估生物标志物和临床指标预测稳定冠心病患者预后的效果的回顾性临床研究。 本研究随机纳入了13164名稳定冠心病患者,评估分析了几种不同的生物标志物和临床指标的预测效果,并基于几个主要的标志物应用多变量Cox回归分析建立一个能预测临床预后的模型。主要终点事件是心源性死亡。经过平均3.7年时间的随访

Heart:不明原因的晕厥和直立性低血压居然有心血管风险!

近期,一项发表在杂志Heart上的研究评估了由于不明原因的晕厥和直立性低血压(OH)引起的住院与随后的心血管事件和死亡率之间的关系。研究者们分析了30528名中年受试者(58±8岁;男性,40%)。应用调整后的Cox回归模型来评估不明原因的晕厥/ OH住院对心血管事件和死亡率的影响,此项研究不包括流行的心血管疾病患者。此项研究结果显示:中位随访15±4年后,分别有524例(1.7%)和504例(1

JACC:PW1在心梗后的心脏重塑中起重要作用

Pw-1基因是成年组织干细胞的标志物,其在心脏中也检测到表达,但具体作用和机制尚未阐明。近日,在国际心血管权威杂志JACC上发表了一篇旨在鉴定心脏表达PW-1的细胞,并研究其在心梗损伤后心肌重塑机制的研究。本研究收集了一份心梗后左室功能下降患者的心脏组织。并且,利用PW1nLacZ+/?报告基因小鼠对正常和左前降支梗死7天的心梗小鼠的表达PW-1的细胞进行鉴别、追踪和分析。研究结果显示,在人群样本

JACC:人类首例经导管大血管吻合术!

目前,对于先天性心脏病的治疗,经导管介入治疗已经代替了许多外科治疗,比如房间隔缺损修补。但是,一些复杂的先心病仍然需要外科的开胸手术治疗,有些甚至需要多期的开胸外科治疗,这就不可避免地伴随着较高的死亡率。近日,在国际心血管权威杂志JACC上发表了一篇旨在评估在一个病人中仅经导管操作行大血管吻合术(上腔静脉和肺动脉吻合术)的可行性的临床研究。 研究者在近十年一直在探索非外科方法的大血管吻合方法